David Farber, Partner in the FDA and Life Sciences practice of the law firm King and Spalding, and a Director of WCGF lent his expertise to a nuanced discussion of the questions surrounding expanded access to experimental drugs for patients seeking drugs outside of clinical trials.  The program, which provided multiple views on state Right-To-Try legislation as well as the Senate’s recent passing of federal Right to Try legislation, aired on NPR’s 1A program on August 7, 2017.

You can listen to the complete program at: